Global stock

NASDAQUSD

argenx SE ADR

ARGX

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

58/ 100

Overall score·ARGX

Current price

873.71USD

23/10/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Růst tržeb a zisku, PEG kolem 1 a forward P/E přibližně 23 ukazují na atraktivní růstový profil, zatímco vysoké P/B a EV/EBITDA naznačují náročnou valuaci. Nejsilnějšími dimenzemi jsou růst a ziskovost; nejslabší je momentum, protože cena klesá a nachází se pod 50denním i 200denním průměrem.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 49%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at argenx SE ADR (ARGX) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

58/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

48/100

Neutral signal based on current news, price action and the economy.

34/100

A lower score means the stock is expensive relative to the company's earnings and assets.

314% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+59%

How fast the company's revenue grows year on year.

82/100

How much the company earns from each unit of revenue and from invested capital.

65/100

Debt level, share-price volatility and how resilient the company is in bad times.

78/100

AI estimate of management quality, execution and capital allocation.

76/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Karen Massey je CEO, Karl Gubitz CFO a Peter Ulrichts Chief Scientific Officer; spoluzakladatel Timothy Van Hauwermeiren zastává funkci předsedy představenstva. Strategie společnosti stojí na rozvoji Vyvgartu a rozšiřování jeho použití do dalších autoimunitních indikací.

Articles about argenx SE ADR, in Czech (1)

Argenx po výsledcích za třetí čtvrtletí čelí otázkám kolem marží

Argenx ve třetím čtvrtletí 2026 vykázal tržby 1,751 miliardy dolarů a zisk na akcii 8,07 dolaru, meziročně výrazně více. Investoři současně řeší pokles čisté marže a růst nákladů na vývoj a provoz.

24 October 2026· 2 min

§ Upcoming results

22 October 2026

Expected

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is argenx SE ADR (ARGX)?

argenx SE ADR (ARGX) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the argenx SE ADR price today?

As of 23 October 2026, argenx SE ADR trades at about 873.71 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy argenx SE ADR?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does argenx SE ADR pay a dividend?

argenx SE ADR either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is argenx SE ADR a good investment in 2026?

Our AI signal currently rates argenx SE ADR as neutral (score 48/100). Financial health comes out at 58/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 314 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy argenx SE ADR

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Neutral

News summary

Older news

Signal 25/10, 15:01

Zprávy k výsledkům Q3 upozorňují na otázku, zda je růst argenx po pětiletém zhodnocení o 202 % již oceněn; další vývoj tržeb a marží může tento pohled potvrdit či zvrátit.

Růst ceny za týden a nedávný klinický úspěch ALKIVIA podporují výhled, ale měsíční pokles, klesající trend, slabé momentum a RSI 45 jej tlumí. Růstové portfolio podporuje střednědobý obraz, náklady a marže zůstávají nejistotou.

Risks: Další zhoršení marží nebo neúspěch při převodu klinických výsledků do registrací a tržeb by výhled oslabil; potvrzený růst prodejů jej může zlepšit.

More about the signal

Risks: Další zhoršení marží nebo neúspěch při převodu klinických výsledků do registrací a tržeb by výhled oslabil; potvrzený růst prodejů jej může zlepšit.

Signal history· 2

24/1020:0177 · Strongly positive
Argenx oznámil, že studie ALKIVIA fáze 3 splnila hlavní cíl u obou skupin pacientů; dopad posílí další prezentace dat a případný postup k registraci.
24/1015:0252 · NeutralArticle →
argenx po výsledcích za 3. čtvrtletí čelí otázkám ohledně marží; souhrn výsledků uvádí růst prodeje VYVGARTu o 54 %. Dopad závisí na vývoji marží a dalších výsledcích.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Overvalued314% above fair value

211.24

range 171.1 – 265.8

Current price

873.71 USD

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

211.24 USD

range 171.1 USD – 265.8 USD

: 15.0%
: 10.0%
: 9.27 USD

Růst FCF 15 % p.a. zohledňuje rychlý růst tržeb a ziskovosti, ale je konzervativnější než jejich aktuální tempo vzhledem k nejistotě dalšího růstu biotechnologické společnosti. Diskontní sazba 10 % odráží riziko klinického a komerčního vývoje; terminální růst 2,5 % odpovídá dlouhodobému růstu ekonomiky.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

2/ 6

6/6 tests available

1. Below DCF fair value

313.6% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

53% above the 1-year low (663.9 USD to 1,058.9 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 31.2 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 1.0; a lower value means cheaper growth.

6. Analyst price target

32.0% vs. the current price, 23 analysts.

Price vs DCF

Current price

873.7 USD

Low 171.1 USDHigh 265.8 USD

Current priceDCF midpoint: 211.2 USD

Price vs analyst target

Current price

873.7 USD

Low 823.0 USDHigh 1,356.0 USD

Current priceAverage: 1,152.9 USD

DCF gap

above range

313.6% above the DCF midpoint (211.2 USD).

Analyst target

+32.0%

Average target 1,152.9 USD vs. price 873.7 USD.

Analyst consensus

Target range

823.0 USD - 1,356.0 USD

Coverage

23 analysts

Analyst consensus

1.5 / 5

Changes 180 d

+1 / -0

EPS next year

90.6%

Revenue next year

23.2%

Valuation multiples

31.2

23.0

151.8

9.7

817.1

1.0

52-week range53% above the low

663.9 USD1,058.9 USD

95.0%

59.0%

32.3%

23.6%

Price vs 50D-8.4%

Price vs 200D2.6%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Vedení vykazuje dobrou exekuci při komercializaci VYVGART a rozšiřování klinického vývoje, přičemž další výsledky závisejí na úspěchu studií a schvalování.

strong

Konkurenční výhodu podporuje komercializovaný VYVGART, know-how v oblasti FcRn a široká vývojová platforma; její trvanlivost omezuje konkurence a regulační i klinická nejistota.

Information

Type: Global stock
Symbol: ARGX
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 31.2x
: 51.4B USD
: 0.6 %
: -0.04

§ Risk profile

Hodnota akcie je citlivá na klinické výsledky, regulatorní rozhodnutí a tempo růstu prodejů Vyvgartu. Českému investorovi navíc měnové riziko přidává pohyb dolaru vůči koruně.

Ask the AI about argenx SE ADR All signals